Interplay between Epigenetics and Cellular Metabolism in Colorectal Cancer

Abstract

Cellular metabolism alterations have been recognized as one of the most predominant hallmarks of colorectal cancers (CRCs). It is precisely regulated by many oncogenic signaling pathways in all kinds of regulatory levels, including transcriptional, post-transcriptional, translational and post-translational levels. Among these regulatory factors, epigenetics play an essential role in the modulation of cellular metabolism. On the one hand, epigenetics can regulate cellular metabolism via directly controlling the transcription of genes encoding metabolic enzymes of transporters. On the other hand, epigenetics can regulate major transcriptional factors and signaling pathways that control the transcription of genes encoding metabolic enzymes or transporters, or affecting the translation, activation, stabilization, or translocation of metabolic enzymes or transporters. Interestingly, epigenetics can also be controlled by cellular metabolism. Metabolites not only directly influence epigenetic processes, but also affect the activity of epigenetic enzymes. Actually, both cellular metabolism pathways and epigenetic processes are controlled by enzymes. They are highly intertwined and are essential for oncogenesis and tumor development of CRCs. Therefore, they are potential therapeutic targets for the treatment of CRCs. In recent years, both epigenetic and metabolism inhibitors are studied for clinical use to treat CRCs. In this review, we depict the interplay between epigenetics and cellular metabolism in CRCs and summarize the underlying molecular mechanisms and their potential applications for clinical therapy.

SP and KLF Transcription Factors in Cancer Metabolism

“…In colorectal cancer, members of the Krüppel-like family transcription factors act either as activators or suppressors of tumorigenesis by altering the primary energy production associated pathways: glucose and lipids metabolism [ 54 ]. Moreover, extrinsic factors affecting metabolic phenotype have been described.…”

Research on lncRNA CTBP1-DT as a potential therapeutic target to regulate cell function in colorectal cancer

“…Colorectal cancer is a prevalent malignant digestive tract tumor in China with a complex and not fully understood pathogenesis [ 16 ]. Early treatment can enhance patient outcomes and extend the survival time, potentially reaching a 5-year prognosis survival rate of 90% [ 17 ].…”

RAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway

“…Ubiquitination is a significant post-translational modification and is essential for physiological processes such as differentiation, cell survival and immunity [ 22 , 23 , 24 ]. Ubiquitination of proteins may lead to activation or inactivation of some pathways in cancer [ 25 ]. As one of the common oncogenes, c-MYC is closely related to the prognosis, occurrence and development of cancer.…”